MCK logo

McKesson Corporation Stock Price

NYSE:MCK Community·US$94.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 78 Fair Values set on narratives written by author

MCK Share Price Performance

US$757.96
251.71 (49.72%)
8.6% undervalued intrinsic discount
US$829.57
Fair Value
US$757.96
251.71 (49.72%)
8.6% undervalued intrinsic discount
US$829.57
Fair Value
Price US$757.96
AnalystConsensusTarget US$829.57

MCK Community Narratives

AnalystConsensusTarget·
Fair Value US$829.57 8.9% undervalued intrinsic discount

Pharmaceutical Demand And Digital Automation Will Shape Future Markets

0users have liked this narrative
0users have commented on this narrative
42users have followed this narrative

Recent MCK News & Updates

Why Investors Shouldn't Be Surprised By McKesson Corporation's (NYSE:MCK) P/E

Jul 07
Why Investors Shouldn't Be Surprised By McKesson Corporation's (NYSE:MCK) P/E

McKesson Corporation Key Details

US$377.6b

Revenue

US$364.6b

Cost of Revenue

US$13.0b

Gross Profit

US$9.9b

Other Expenses

US$3.2b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 05, 2025
Earnings per share (EPS)
25.44
Gross Margin
3.45%
Net Profit Margin
0.84%
Debt/Equity Ratio
-878.4%

McKesson Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Fair value with limited growth.

1 Risk
3 Rewards

About MCK

Founded
1833
Employees
44000
CEO
Brian Tyler
WebsiteView website
www.mckesson.com

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers deliver medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: 0.3%
  • 3 Months: 8.5%
  • 1 Year: 17.3%
  • Year to Date: 15.0%
The market has stayed flat over the 7 days. As for the longer term, the market has risen 17% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›